

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number
WO 2004/011002 A1

(51) International Patent Classification⁷: **A61K 31/4745**, (74) Agents: **FORBES, James, C. et al.**; **Pharmacia Corporation**, 575 Maryville Centre Drive, 5th Floor, Mail Zone 1006, St. Louis, MO 63141 (US).

(21) International Application Number:

PCT/US2003/023403

(22) International Filing Date: 25 July 2003 (25.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/398,427 25 July 2002 (25.07.2002) US

60/398,447 25 July 2002 (25.07.2002) US

60/479,327 18 June 2003 (18.06.2003) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **PHARMACIA CORPORATION** [US/US]; Global Patent Department, 575 Maryville Centre Drive, 5th Floor, Mail Zone 1006, St. Louis, MO 63141 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **GANORKAR, Loksiddh, D.** [MU/US]; 5307 Willowbend Trail, Kalamazoo, MI 49009 (US). **REO, Joseph, P.** [US/US]; 5914 Bluejay Drive, Kalamazoo, MI 49009 (US). **MARTINO, Alice, C.** [US/US]; 6232 Far Hills Way, Kalamazoo, MI 49009 (US). **AMIDON, Gregory, E.** [US/US]; 7174 Hickory Point Drive, Portage, MI 49024 (US). **SKOUG, Connie, J.** [US/US]; 9942 Wexford Drive, Portage, MI 49024 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUSTAINED-RELEASE TABLET COMPOSITION COMPRISING A DOPAMINE RECEPTOR AGONIST



(57) Abstract: A sustained-release pharmaceutical composition on a form of an orally deliverable tablet comprises as active pharmaceutical agent a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R¹, R² and R³ are the same or different and are H, C₁₋₆ alkyl (optionally phenyl substituted), C₃₋₅ alkenyl or alkynyl or C₃₋₁₀cycloalkyl, or where R³ is as above and R¹ and R² are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups; X is H, F, Cl, Br, I, OH, C₁₋₆ alkyl or alkoxy, CN, carboxamide, carboxyl or (C₁₋₆ alkyl)carbonyl; A is CH, CH₂, CHF, CHCl, CHBr, CHI, CHCH₃, C=O, C=S, CSCH₃, C=NH, CNH₂, CNHCH₃, CNHCOOCH₃, CNHCN, SO₂ or N; B is CH, CHZ, CH₂, CHCl, CHBr, CHI, C=O, N, NH or NCH₃, and n is 0 or 1; and D is CH, CH₂, CHF, CHCl, CHBr, CHI, C=O, O, O, NH or NCH₃. The agent is dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm⁻² at a solid fraction representative of the tablet. The composition exhibits sustained-release properties effective for treatment of Parkinson's disease. The tablet is optionally coated. Tablets of the invention have improved resistance to attrition or erosion during manufacture, packaging and handling.

WO 2004/011002 A1

SUSTAINED-RELEASE TABLET COMPOSITION COMPRISING A DOPAMINE
RECEPTOR AGONIST

FIELD OF THE INVENTION

[0001] The present invention relates to tablet formulations, and more particularly to a sustained-release tablet composition for oral delivery of a water-soluble dopamine receptor agonist.

BACKGROUND OF THE INVENTION

[0002] Many active pharmaceutical agents, including drugs and prodrugs, have been formulated as orally deliverable dosage forms providing sustained release (otherwise known as slow release or extended release) of such agents over a period of time effective to permit once daily administration. A well-known system for formulating such dosage forms involves a matrix comprising a hydrophilic polymer wherein the agent is dispersed; the agent is released over a period of time in the gastrointestinal tract upon dissolution or erosion of the matrix. Sustained-release dosage forms comprising such a matrix system are conveniently prepared as compressed tablets, described herein as "matrix tablets".

[0003] Drugs and prodrugs having relatively high solubility in water, for example a solubility of about 10 mg/ml or greater, present challenges to the formulator wishing to provide a sustained-release dosage form, and the higher the solubility the greater are the challenges. These challenges are well illustrated in the case of sumanirole maleate.

[0004] Sumanirole is a highly selective dopamine D₂ receptor agonist useful in treatment of a variety of conditions and disorders of the central nervous system (CNS) including Parkinson's disease, restless legs syndrome and sexual dysfunction. The maleate salt of sumanirole has been selected based on its physical and chemical properties. This salt is highly soluble.

[0005] U.S. Patent No. 6,197,339 discloses a sustained-release tablet comprising (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) (sumanirole maleate) in a matrix comprising hydroxypropylmethylcellulose (HPMC) and starch. The tablet is disclosed to be useful in treatment of Parkinson's disease. Starches disclosed to be suitable therein include pregelatinized starch.

[0006] European Patent Application No. EP 0 933 079 discloses a starch said to be suitable for preparing tablets having high hardness yet being capable of rapid disintegration in an aqueous medium. Tensile strength of the finished tablets is calculated

from the hardness.


[0007] Patents and publications cited above are incorporated herein by reference.

[0008] Tablets prepared as described in above-cited U.S. Patent No. 6,197,339 exhibit good therapeutic effectiveness but can be susceptible to attrition and/or erosion during manufacture, packaging and handling.

[0009] It is an object of the present invention to provide a sustained-release tablet composition of a water-soluble dopamine receptor agonist, the tablet having sufficient hardness to withstand a high-speed tableting and/or coating operation, in particular to resist erosion during such an operation.

SUMMARY OF THE INVENTION

[0010] There is now provided a sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprising as active pharmaceutical agent a compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein

R¹, R² and R³ are the same or different and are H, C₁₋₆ alkyl (optionally phenyl substituted), C₃₋₅ alkenyl or alkynyl or C₃₋₁₀ cycloalkyl, or where R³ is as above and R¹ and R² are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups;

X is H, F, Cl, Br, I, OH, C₁₋₆ alkyl or alkoxy, CN, carboxamide, carboxyl or (C₁₋₆ alkyl)carbonyl;

A is CH, CH₂, CHF, CHCl, CHBr, CHI, CHCH₃, C=O, C=S, CSCH₃, C=NH, CNH₂, CNHCH₃, CNHCOOCH₃, CNHCN, SO₂ or N;

B is CH, CH₂, CHF, CHCl, CHBr, CHI, C=O, N, NH or NCH₃, and n is 0 or 1; and

D is CH, CH₂, CHF, CHCl, CHBr, CHI, C=O, O, N, NH or NCH₃.

[0011] It is preferred that the compound of formula (I) or salt thereof has water solubility of at least about 10 mg/ml, more preferably at least about 50 mg/ml and most preferably at least about 100 mg/ml.

[0012] The active pharmaceutical agent is dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm⁻² at a solid fraction representative of the tablet.

[0013] There is further provided a process for preparing a sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprising as active pharmaceutical agent a compound of formula (I) or a salt thereof, the process comprising selecting by a suitable test a starch having a tensile strength of at least about 0.15 kN cm⁻² at a solid fraction representative of the tablet; admixing with the selected starch a hydrophilic polymer and the agent to provide a mixture wherein the agent is dispersed in a matrix comprising the polymer and the starch; and compressing the mixture to form a tablet.

[0014] A particularly convenient test method, which is itself a further embodiment of the invention, comprises preparing compacts of a starch sample on an automated tablet press at a range of compression forces, measuring hardness of the compacts, determining solid fraction of the compacts, calculating tensile strength of the compacts from hardness and dimensions of the compacts, determining relationship of tensile strength to solid fraction of the compacts, and from that relationship estimating tensile strength at a solid fraction representative of a desired tablet.

[0015] There is still further provided a method of treatment of a subject having a condition or disorder for which a dopamine agonist is indicated, the method comprising orally administering to the subject a sustained-release pharmaceutical composition in a form of a tablet comprising as active pharmaceutical agent a compound of formula (I) or salt thereof, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm⁻² at a solid fraction representative of the tablet.

[0016] An "active pharmaceutical agent" herein can be a drug or a prodrug or a salt thereof, including diagnostic agents. Unless otherwise specified, "solubility" herein means solubility in water at 20–25°C at any physiologically acceptable pH, for example at any pH in the range of about 4 to about 8. In the case of an agent that is a salt, reference herein to solubility in water pertains to the salt, not to the free acid or base form

of the agent.

[0017] The term "orally deliverable" herein means suitable for oral, including peroral and intra-oral (*e.g.*, sublingual or buccal) administration, but tablets of the present invention are adapted primarily for peroral administration, *i.e.*, for swallowing, typically whole and with the aid of water or other drinkable fluid.

[0018] A "compact" herein is a compressed tablet, prepared for example on a tablet press, consisting only of a sample of starch for which it is desired to measure tensile strength. "Solid fraction" is the ratio of absolute to apparent density of a compact. A "solid fraction representative of the tablet" is a solid fraction selected to be similar to the solid fraction of tablets prepared according to the invention. Typically a solid fraction of about 0.75 to about 0.85, illustratively 0.8, will be selected.

[0019] A "subject" herein is an animal of any species, preferably mammalian, most preferably human. Conditions and disorders in a subject for which a particular agent is said herein to be "indicated" are not restricted to conditions and disorders for which the agent has been expressly approved by a regulatory authority, but also include other conditions and disorders known or believed by a physician to be amenable to treatment with the agent. "Treatment" herein embraces prophylactic treatment unless the context requires otherwise.

BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Fig. 1 is a graph showing relationship of tensile strength of pregelatinized starch lots, as determined by a test method of the invention using a 4 second dwell time (Example 1 herein) to triaxial tensile strength.

[0021] Fig. 2 is a graph showing relationship of tensile strength of pregelatinized starch lots, as determined by a test method of the invention using a 90 second dwell time (Example 1 herein) to triaxial tensile strength.

[0022] Fig. 3 is a graph showing correlation of tensile strength of pregelatinized starch lots with maximum hardness of tablets containing these lots.

DETAILED DESCRIPTION OF THE INVENTION

[0023] In one embodiment, the invention provides a pharmaceutical composition in a form of an orally deliverable tablet comprising as active pharmaceutical agent a compound of formula (I) or a salt thereof.


[0024] Pharmaceutically acceptable salts of a compound of formula (I) include

without restriction salts of the following acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, phosphoric, nitric, lactic, malic, benzoic, citric, tartaric, fumaric and maleic acids, and mono- and dicarboxylic acids of formulas $\text{CH}_3\text{-(CH}_2\text{)}_n\text{-COOH}$ and $\text{HOOC-(CH}_2\text{)}_n\text{-COOH}$ where n is 0 to 4, for example acetic, propionic, malonic and succinic acids.

[0025] Particularly preferred salts are the hydrochloride salt and the maleate, *i.e.*, (*Z*)-2-butenedioate, salt.

[0026] Compounds of formula (I) and their salts can be prepared by processes known *per se*, including processes described in patent literature cited herein. However, the present invention is not restricted by the process used to prepare the therapeutic agent.

[0027] Preferred compounds of formula (I) include those disclosed generically or specifically in U.S. Patent No. 5,273,975, which is incorporated herein by reference. Especially preferred compounds are salts of sumanirole, in the form of its R-enantiomer, (*R*)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-*ij*]-quinolin-2(1*H*)-one (II), and its thione counterpart (*R*)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-*ij*]-quinoline-2(1*H*)-thione (III).



[0028] In the case of either compound (II) or (III), suitable salts include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, maleate, malate, succinate, tartrate, cyclohexanesulfamate, mesylate (methanesulfonate), esylate (ethanesulfonate), besylate (benzenesulfonate) and tosylate (*p*-toluenesulfonate) salts. The maleate salt is preferred. Use of this salt in treatment of restless legs syndrome is specifically disclosed in International Patent Publication No. WO 02/36123.

[0029] The amount of the active pharmaceutical agent present in a composition of the invention depends on the potency of the agent, but is preferably sufficient to provide a daily dose in one to a small plurality, for example one to about 4, of tablets to be administered no more than twice daily. Preferably a single tablet provides a sufficient

amount of the agent for each administration. In most cases the amount of the agent per tablet is about 0.1 to about 200 mg, preferably about 0.2 to about 100 mg. Expressed as percentage by weight of the composition, the amount of the agent is typically about 0.01% to about 25%, preferably about 0.05% to about 20%. In the case of an agent that is a salt, amounts of agent herein are expressed as free acid or free base equivalent amounts, unless otherwise specified.

[0030] Illustratively in the case of sumanirole, an amount of about 0.5 to about 25 mg per tablet, or about 0.1% to about 15% by weight of the composition, will generally be suitable. Specific dosage amounts per tablet contemplated herein include 0.5, 1, 2, 4, 8, 12 and 24 mg sumanirole in the form of sumanirole maleate.

[0031] A composition of the present invention comprises an active pharmaceutical agent as defined above, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm^{-2} at a solid fraction representative of the tablet, for example about 0.75 to about 0.85, illustratively 0.8.

[0032] Hydrophilic polymers useful herein are pharmaceutically acceptable polymeric materials having a sufficient number and distribution of hydrophilic substituents such as hydroxy and carboxy groups to impart hydrophilic properties to the polymer as a whole. Suitable hydrophilic polymers include, without limitation, methylcellulose, HPMC (hypromellose), carmellose (carboxymethylcellulose) sodium and carbomer (polyacrylic acid). More than one such polymer can optionally be used.

[0033] HPMC is a preferred hydrophilic polymer. Various types and grades of HPMC are available. In one embodiment HPMC type 2208, preferably meeting specifications set forth in a standard pharmacopeia such as USP 24, is used. HPMC type 2208 contains 19–24% by weight methoxy and 4–12% by weight hydroxypropoxy substituents. Especially suitable HPMCs have nominal viscosity ranging from about 100 to about 10,000 mPa s; illustratively a suitable HPMC type 2208 is one having a nominal viscosity of about 4,000, with a measured viscosity of about 3,000 to about 5,600 mPa s. Such an HPMC is available, for example, as Methocel® K4MP from Dow Chemical Co., and substantially equivalent products are available from other manufacturers.

[0034] The amount of hydrophilic polymer in the composition depends on the particular polymer selected, on the active pharmaceutical agent and on the desired sustained release profile. Typically, however, the hydrophilic polymer is included in an amount of about 20% to about 70%, preferably about 30% to about 60% and more

preferably about 35% to about 50%, by weight of the composition. In the illustrative case of HPMC type 2208, a suitable amount will generally be found in the range from about 30% to about 60%, preferably about 35% to about 50%, for example about 40%, by weight of the composition.

[0035] It is believed, without being bound by theory, that the hydrophilic polymer functions to provide extended or sustained release of the active pharmaceutical agent, for example by gradual dissolution or erosion of the polymer in the gastrointestinal tract.

[0036] Starches useful herein include starches from any suitable botanical source, for example corn, wheat, rice, tapioca, potato, etc., so long as they meet the requirement herein that their tensile strength is at least about 0.15 kN cm^{-2} at a solid fraction representative of the tablet. Preferred starches have a relatively high amylose/amylopectin ratio, containing for example at least about 20%, more preferably at least about 25%, amylose. Especially preferred is pregelatinized starch, which is a type of modified starch that has been processed to render the starch more flowable and directly compressible. Partially or wholly pregelatinized starches can be used.

[0037] It is believed, without being bound by theory, that the primary function of the starch in a composition of the invention is as a binding agent. A starch meeting the tensile strength criterion defined herein can be referred to as a "super binder".

[0038] The amount of starch in the composition is typically higher than is conventionally present as a binder in tablet formulations. Suitable amounts will generally be found in the range of about 25% to about 75% by weight. Preferably the amount of starch is about 40% to about 70%, more preferably about 45% to about 65%, for example about 50%, by weight of the composition.

[0039] Tensile strength of a starch sample can be measured by any suitable test. Illustrative test procedures are described by Hiestand & Smith (1984), *Powder Technology* 38, 145–159, and by Hiestand & Smith (1991), *International Journal of Pharmaceutics* 67, 231–246, these articles being incorporated herein by reference.

[0040] An example of a tensile strength test that can be used (herein referred to as a "triaxial tensile strength test") requires preparation of a series of compacts of the starch sample, followed by determination of tensile strength of the compacts using a computerized multifunction tablet tester (MTT). The compacts are prepared with various degrees of compression force to provide compacts having a range of solid fraction. As a sustained release tablet formulation typically has a solid fraction of about 0.8, it is useful

to prepare compacts approximating such a solid fraction.

[0041] Absolute density of the starch sample can be determined using a helium-air pycnometer.

[0042] A computer-controlled triaxial tablet press is used to prepare the compacts. Voltage output from the punch and die load cells of the tablet press are first zeroed. The punch and die are lubricated with magnesium stearate powder and the die assembly is placed in the press. Compression and decompression parameters are selected on the computer. The desired amount of starch to be compacted is weighed and poured into the die cavity. The resulting powder bed is leveled with a spatula. The punch is inserted into the die and the computer-controlled compression/decompression cycle is started.

[0043] Just prior to the end of the compression phase, thickness of the compact as measured by LVDT is recorded. At the end of the compression phase, the final compression force as measured by voltage of the punch load cell is recorded.

[0044] At the end of the decompression phase, the punch and die rams are retracted. The compact is removed from the die and inspected for defects, such as cracking or sticking. Cracking can be reduced by increasing decompression time. If the compact is free of defects, its length, width, thickness and weight are measured to enable calculation of apparent density. Solid fraction is calculated by dividing absolute density by apparent density.

[0045] In preparation of the MTT for tensile strength determination, a suitable software program is run. The platen is screwed to the load cell of the MTT and the tensile strength assembly is slid into the MTT opposite the platen. The load cell signal is monitored via the computer and the zero offset on the signal conditioner is adjusted to provide a positive baseline voltage as close as possible to zero. A forward velocity is selected that will generate a time constant of approximately 15 seconds (usually the velocity selected will be about 0.8 to about 1.2 mm s⁻¹).

[0046] The compact to be tested is placed in the holder of the tensile strength assembly. The motor is initiated via the computer, driving the platen toward the compact until the surface of the compact is detected, and stopping the platen a few millimeters from the compact. The oscilloscope is triggered, to record the force applied to the compact, and the motor is restarted. The platen is driven into the compact until a crack is detected, either by sight or by sound, and the motor is immediately reversed.

[0047] Peak force is recorded from the oscilloscope trace. Tensile strength is

calculated from the peak force using appropriate computer software.

[0048] From several runs using compacts at a range of solid fractions around 0.8, data are plotted and tensile strength at a solid fraction of 0.8 is estimated. If the tensile strength at a solid fraction of 0.8 is about 0.15 kN cm⁻² or greater, the starch sample is deemed to be suitable for use in preparing a composition according to the invention.

[0049] It has now surprisingly been discovered that a much simpler test, one that is more amenable to implementation in a manufacturing setting, can be used to estimate tensile strength of a starch sample, in particular to determine whether the starch sample has a tensile strength of at least about 0.15 kN cm⁻² at a solid fraction representative of a desired sustained-release tablet.

[0050] According to this test, compacts of the starch sample are prepared on a standard automated tablet press under a range of compression forces. For example, a Carver press (e.g., Model 3888.1DT0000) fitted with flat-faced tooling of suitable diameter (e.g., 10/32 inch or about 0.7 cm for a 300 mg compact), operated at compression forces of about 4 to about 16 kN (about 900 to about 3600 lbf) for a dwell time of at least about 4 seconds has been found to give satisfactory results. Illustratively, such compacts can be prepared at 1000, 1500, 2000 and 3000 lbf (4.45, 6.67, 8.90 and 13.34 kN). Preferably a dwell time of at least about 10 seconds, more preferably at least about 30 seconds, still more preferably at least about 60 seconds, is used. Illustratively, a dwell time of 90 seconds has been found to give satisfactory results. Weight, diameter and thickness of each compact are measured accurately (alternatively, diameter can be assumed to equal that of the tooling) to enable calculation of apparent density and hence solid fraction, absolute density having been measured as described above, for example by helium-air pycnometry.

[0051] Hardness of each compact thus prepared is then determined by any suitable tablet hardness test, for example using a Key HT 500 hardness tester. Hardness is a measure of the force required to cause crushing of the compact, and is typically expressed in units such as kiloponds (kp) or Strong-Cobb units (SCU). A hardness of about 10.2 kp or about 14.4 SCU corresponds to a force of 0.1 kN.

[0052] For present purposes it is considered that crushing strength of the compact is equivalent to tensile strength. Thus tensile strength (σ_T , in kN cm⁻²) can be calculated from the equation

$$\sigma_T = 2F/\pi DH$$

where F is the force required to cause crushing (in kN), D is diameter of the compact (in cm) and H is thickness of the compact (in cm). For example, a compact of diameter 0.7 cm and thickness 0.4 cm having a hardness of 20 SCU (equivalent to a force of 0.139 kN) has a calculated tensile strength of 0.316 kN cm^{-2} .

[0053] The relationship between tensile strength and solid fraction is next established for the starch sample. This can be done by plotting data for tensile strength and solid fraction on a graph (solid fraction tends to increase with increasing compression force during preparation of the compact) or by performing a regression analysis. From that relationship, tensile strength at a standardized value of solid fraction can be estimated. The standardized value selected is one that is representative of the solid fraction of a desired sustained-release tablet, e.g., 0.8.

[0054] Where the material of the compact is pregelatinized starch, it has been found that tensile strength as determined in a simple test as described immediately above is surprisingly close to a "true" tensile strength measurement as determined by the triaxial tensile strength test method previously described, which in turn is essentially similar to methods known in the art such as that disclosed by Hiestand & Smith (1984), *op. cit.*

[0055] It has also been found that a longer dwell time (e.g., 90 seconds) in the test method of the present invention gives a better correlation with triaxial tensile strength than a very short dwell time (e.g., 4 seconds). See Example 1 below and Figs. 1 and 2.

[0056] An especially preferred starch has a tensile strength of at least about 0.175 kN cm^{-2} , even more preferably at least about 0.2 kN cm^{-2} , at a solid fraction representative of a desired sustained-release tablet.

[0057] Even among commercially available pregelatinized starches, the preferred type of starch for use in a composition of the invention, considerable variation exists in tensile strength. Pregelatinized starches not meeting the tensile strength criterion established herein are not readily identified without testing, for example by a method as disclosed above. Such pregelatinized starches are generally unsuitable for commercial-scale manufacture of a sustained-release matrix tablet formulation as defined herein, because of a problem as set forth immediately below.

[0058] An uncoated tablet, or a tablet core prior to coating, comprising starch and a hydrophilic polymer acting as a matrix for a water-soluble drug or prodrug requires to have a certain minimum hardness in order to be able to resist breakage and/or attrition due to mechanical stresses imposed during a high-speed tableting operation (including all

steps up to and including filling of the tablets into containers). The minimum acceptable hardness will depend on a number of factors, including the severity of the mechanical stresses, but is typically at least about 20 SCU, preferably at least about 22 SCU, more preferably at least about 24 SCU (about 17 kp).

[0059] Hardness can be increased by increasing the compression force applied by the tablet press, but only up to a certain level. At least in the case of tablets as described herein, above a certain compression force, further increases in compression force give little or no further increase in tablet hardness. There is, in other words, a maximum hardness achievable by compression of a particular starch/hydrophilic polymer/active agent composition. A starch providing a maximum hardness inadequate to withstand the mechanical stresses of a high-speed tableting and/or coating operation is unsuitable for the present purpose. As shown in Fig. 3, certain pregelatinized starches have been found to provide a maximum hardness of 20 SCU or less; these are now identified as starches having low tensile strength (0.1 kN cm^{-2} or less according to the test method of the invention utilizing a dwell time of 90 seconds).

[0060] Even if a maximum hardness of at least about 20 SCU is achievable, with a starch of low tensile strength it may be achievable only by use of extremely high compression forces. A requirement for such forces reduces speed and efficiency and increases cost of a tableting operation and is undesirable for these reasons.

[0061] Where tablets are to be subjected to an additional process step after compression, in particular a coating step, exposure to mechanical stresses is further increased. According to one embodiment, therefore, the sustained-release tablet of the invention further comprises a coating, for example a nonfunctional coating. A nonfunctional coating can comprise a polymer component, for example HPMC, optionally with other ingredients, for example one or more plasticizers, colorants, etc. The term "nonfunctional" in the present context means having substantially no effect on release properties of the tablet, and should not be read to imply that the coating serves no useful purpose. For example, such a coating can impart a distinctive appearance to the tablet, provide protection against attrition during packaging and transportation, improve ease of swallowing, and/or have other benefits.

[0062] Uncoated tablets and cores of coated tablets of the invention can optionally contain one or more pharmaceutically acceptable excipients in addition to the starch and hydrophilic polymer components described above. Such excipients include without

limitation glidants and lubricants. Other conventional excipients known in the art can also be included.

[0063] A glidant can be used to improve powder flow properties prior to and during tabletting and to reduce caking. Suitable glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate and the like. In one embodiment, colloidal silicon dioxide is included as a glidant in an amount up to about 2%, preferably about 0.2% to about 0.6%, by weight of the tablet.

[0064] A lubricant can be used to enhance release of a tablet from apparatus on which it is formed, for example by preventing adherence to the face of an upper punch ("picking") or lower punch ("sticking"). Suitable lubricants include magnesium stearate, calcium stearate, canola oil, glycetyl palmitostearate, hydrogenated vegetable oil, magnesium oxide, mineral oil, poloxamer, polyethylene glycol, polyvinyl alcohol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, hydrogenated vegetable oil, zinc stearate and the like. In one embodiment, magnesium stearate is included as a lubricant in an amount of about 0.1% to about 1.5%, preferably about 0.3% to about 1%, by weight of the tablet.

[0065] Tablets can be of any suitable size and shape, for example round, oval, polygonal or pillow-shaped, and optionally bear nonfunctional surface markings. They are preferably designed to be swallowed whole and are therefore typically not provided with a breaking score. Tablets of the invention can be packaged in a container, accompanied by a package insert providing pertinent information such as, for example, dosage and administration information, contraindications, precautions, drug interactions and adverse reactions.

[0066] There is also provided a method of treatment of a subject having a condition or disorder for which a dopamine agonist is indicated, the method comprising orally administering to the subject a sustained-release pharmaceutical composition in a form of a tablet comprising as active pharmaceutical agent a compound of formula (I) or a salt thereof dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm⁻² at a solid fraction representative of the tablet.

[0067] Preferably the composition is administered no more than twice daily.

[0068] Preferably the active pharmaceutical agent is a salt of sumanirole (II) or the compound of formula (III), most preferably the maleate. These agents are especially

useful in treatment of Parkinson's disease, but can also be used for treatment of sexual dysfunction.

[0069] Illustratively in the case of sumanirole, suitable dosage amounts to be administered no more than twice daily include 0.5, 1, 2, 4, 8, 12 and 24 mg sumanirole in the form of sumanirole maleate.

EXAMPLES

Example 1

[0070] Tensile strength of six commercially obtained lots of pregelatinized starch was determined using the triaxial tensile strength test procedure described hereinabove. Data for tensile strength at a solid fraction of 0.8 are presented in Table 1.

**Table 1. Tensile strength of pregelatinized starch lots at a solid fraction of 0.8
(triaxial test procedure)**

Lot	Tensile strength (kN cm ⁻²)
1	0.323
2	0.220
3	0.074
4	0.119
5	0.287
6	0.236

[0071] A great variation in tensile strength of pregelatinized starches was observed, ranging from 0.074 to 0.323 kN cm⁻². Lots 3 and 4, exhibiting the lowest values of tensile strength, were from one manufacturer. Lots 1, 5 and 6, exhibiting the highest values of tensile strength, were from a second manufacturer. Lot 2, exhibiting an intermediate value of tensile strength, was from a third manufacturer.

Example 2

[0072] Tensile strength of the same six lots of pregelatinized starch was determined by the following simplified test procedure.

[0073] Compacts of each starch lot were prepared on a Carver press, Model 3888.1DT0000 fitted with 10/32 inch (0.7 cm) flat-faced tooling, at compression forces of 1000, 1500, 2000 and 3000 lbf (4.45, 6.67, 8.90 and 13.34 kN), for a dwell time of 4 seconds or 90 seconds. Compacts of an additional three lots of pregelatinized starch (Lots 7, 8 and 9), from the same manufacturer as Lots 3 and 4, were prepared using a dwell time of 90 seconds only. Weight and thickness of each compact was measured

(diameter being equal to that of the tooling) to enable calculation of apparent density. Absolute density of each starch lot was measured by helium-air pycnometry. Solid fraction was calculated as the ratio of apparent to absolute density.

[0074] Hardness (force required to cause crushing) of each compact was determined using a Key HT 500 hardness tester. Tensile strength was calculated from this force and dimensions of the compact, using the equation

$$\sigma_T = 2F/\pi DH$$

as described hereinabove.

[0075] A regression analysis was performed to determine the relationship of tensile strength to solid fraction for each starch lot, and tensile strength at a standardized solid fraction of 0.8 was calculated. Data are presented in Table 2.

**Table 2. Tensile strength of pregelatinized starch lots at a solid fraction of 0.8
(simplified test procedure of the invention)**

Lot	Tensile strength (kN cm ⁻²)	
	4 s dwell time	90 s dwell time
1	0.310	0.306
2	0.227	0.191
3	0.092	0.085
4	0.134	0.096
5	0.316	0.277
6	0.333	0.242
7	n.d.	0.087
8	n.d.	0.088
9	n.d.	0.172

[0076] Correlation of tensile strength as measured in the simplified test using a 4 second dwell time (this Example) with tensile strength as measured by the triaxial test procedure of Example 1 is shown graphically in Fig. 1.

[0077] Correlation of tensile strength as measured in the simplified test using a 90 second dwell time (this Example) with tensile strength as measured by the triaxial test procedure of Example 1 is shown graphically in Fig. 2.

[0078] Both dwell times exhibited a strong correlation, but the correlation was especially close where the simplified test used a 90 second dwell time. It is concluded that the simplified test as herein described can be used to estimate tensile strength of a starch lot for the purpose of predicting whether that starch lot will be suitable for preparing a sustained-release tablet formulation of the present invention.

Example 3

[0079] Sumanirole maleate sustained-release tablets were prepared having the compositions shown in Table 3. Tablet strength in mg is expressed as sumanirole base.

Table 3. Composition of sumanirole maleate tablets of Example 3

Ingredient	Tablet strength (mg)							
	0.5	1	2	4	8	8	12	24
	Amount (% by weight)							
sumanirole maleate	0.23	0.45	0.9	1.8	3.6	3.6	5.4	10.9
HPMC type 2208, 4000 mPa s	35.00	35.00	35.0	35.0	35.0	35.0	35.0	35.0
pregelatinized starch	63.87	63.65	63.2	62.3	60.5	60.0	58.2	52.5
colloidal silicon dioxide	0.40	0.40	0.4	0.4	0.4	0.4	0.4	0.4
magnesium stearate	0.50	0.50	0.5	0.5	0.5	1.0	1.0	1.0

[0080] All ingredients except the lubricant (magnesium stearate) were screened to remove lumps and were blended thoroughly in a low-shear mixer operating at 24 rpm for 10–30 minutes. The lubricant was then screened into the mixer and the materials were blended for a further 2–5 minutes. The resulting lubricated mixture was compressed into 350 mg pillow-shaped tablets using a Kilian S100 tabletting machine.

Example 4


[0081] Tablets similar to those of Example 3 were prepared using pregelatinized starches of lots 1–6 as tested in Examples 1 and 2. Maximum hardness of the tablets obtainable with each pregelatinized starch lot was determined.

[0082] Maximum hardness was correlated with tensile strength of the pregelatinized starch lot used, as measured in the simplified test of Example 2 using a 90 second dwell time. Results are shown in Fig. 3. The correlation was substantially linear.

[0083] In subsequent tests, tablets of different hardness were used as cores for coating and were tested for resistance to erosion during a high-speed coating operation. Tablet cores having a hardness of at least about 24 SCU (about 17 kp) were found to have acceptable resistance to erosion. As shown in Fig. 3, this degree of hardness is achievable using pregelatinized starch having a tensile strength of at least about 0.175 kN cm⁻². Pregelatinized starches of Lots 3 and 4 were unsuitable, having tensile strength less than about 0.15 kN cm⁻² and providing tablets having a maximum hardness no greater than about 20 SCU (about 14 kp).

WHAT IS CLAIMED IS:

1. A pharmaceutical composition in a form of an orally deliverable tablet comprising as active pharmaceutical agent a compound of formula



or a pharmaceutically acceptable salt thereof, wherein

R¹, R² and R³ are the same or different and are H, C₁₋₆ alkyl (optionally phenyl substituted), C₃₋₅ alkenyl or alkynyl or C₃₋₁₀ cycloalkyl, or where R³ is as above and R¹ and R² are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups;

X is H, F, Cl, Br, I, OH, C₁₋₆ alkyl or alkoxy, CN, carboxamide, carboxyl or (C₁₋₆ alkyl)carbonyl;

A is CH, CH₂, CHF, CHCl, CHBr, CHI, CHCH₃, C=O, C=S, CSCH₃, C=NH, CNH₂, CNHCH₃, CNHCOOCH₃, CNHCN, SO₂ or N;

B is CH, CH₂, CHF, CHCl, CHBr, CHI, C=O, N, NH or NCH₃, and n is 0 or 1; and

D is CH, CH₂, CHF, CHCl, CHBr, CHI, C=O, O, N, NH or NCH₃;

said compound or salt thereof being dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm⁻², preferably at least about 0.175 kN cm⁻², and more preferably at least about 0.2 kN cm⁻², at a solid fraction representative of the tablet.

2. The composition of Claim 1 wherein the starch is a pregelatinized starch.
3. The composition of any of the preceding claims wherein the starch is present in an amount of about 25% to about 75%, preferably about 40% to about 70%, and more preferably about 45% to about 65%, by weight.
4. The composition of any of the preceding claims wherein the hydrophilic polymer is selected from the group consisting of methylcellulose,


hydroxypropylmethylcellulose, carmelloose sodium and carbomer.

5. The composition of any of the preceding claims wherein the hydrophilic polymer is hydroxypropylmethylcellulose.
6. The composition of any of the preceding claims wherein the hydrophilic polymer is present in an amount of about 20% to about 70%, preferably about 30% to about 60%, and more preferably about 35% to about 50%, by weight.
7. The composition of any of the preceding claims wherein the active pharmaceutical agent has solubility not less than about 10 mg/ml, preferably not less than about 50 mg/ml, and more preferably not less than about 100 mg/ml.
8. The composition of any of the preceding claims wherein the active pharmaceutical agent is a salt of sumanirole.
9. The composition of Claim 8 wherein the salt is sumanirole maleate.
10. The composition of either of Claims 8 or 9 that comprises about 0.5 to about 25 mg sumanirole per tablet, preferably about 0.5, 1, 2, 4, 8, 12 or 24 mg sumanirole per tablet.
11. The composition of any of Claims 1 to 7 wherein the active pharmaceutical agent is a salt of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(1H)-thione.
12. The composition of Claim 11 wherein the salt is the maleate salt.
13. A pharmaceutical composition in a form of an orally deliverable tablet comprising sumanirole maleate in an amount of about 0.5, 1, 2, 4, 8, 12 or 24 mg, dispersed in a matrix comprising (a) hydroxypropylmethylcellulose type 2208 in an amount of about 35% to about 50% by weight of the tablet and (b) a pregelatinized starch having a tensile strength of at least about 0.15 kN cm^{-2} at a solid fraction of 0.8, in an amount of about 45% to about 65% by weight of the tablet.
14. A method of treatment of a subject having a condition or disorder for which a dopamine agonist is indicated, the method comprising orally administering to the subject the pharmaceutical composition of any of the preceding claims.
15. The method of Claim 14 wherein the composition is administered no more than once daily.

16. The method of either of Claims 14 or 15 wherein the condition or disorder is Parkinson's disease.

17. The method of either of Claims 14 or 15 wherein the condition or disorder is sexual dysfunction.

18. A process for preparing a sustained-release pharmaceutical composition in a form of an orally deliverable tablet, the process comprising selecting by a suitable test a starch having a tensile strength of at least about 0.15 kN cm^{-2} at a solid fraction representative of the tablet; admixing with the selected starch a hydrophilic polymer and an active pharmaceutical agent that is a compound of formula



or a pharmaceutically acceptable salt thereof, wherein

R^1 , R^2 and R^3 are the same or different and are H, C_{1-6} alkyl (optionally phenyl substituted), C_{3-5} alkenyl or alkynyl or C_{3-10} cycloalkyl, or where R^3 is as above and R^1 and R^2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups;

X is H, F, Cl, Br, I, OH, C_{1-6} alkyl or alkoxy, CN, carboxamide, carboxyl or $(C_{1-6}$ alkyl)carbonyl;

A is CH, CH_2 , CHF, CHCl , CHBr , CHI, CHCH_3 , C=O, C=S, CSCH_3 , C=NH, CNH_2 , CNHCH_3 , CNHCOOCH_3 , CNHCN , SO_2 or N;

B is CH, CH_2 , CHF, CHCl , CHBr , CHI, C=O, N, NH or NCH_3 , and n is 0 or 1; and

D is CH, CH_2 , CHF, CHCl , CHBr , CHI, C=O, O, N, NH or NCH_3 ;

to provide a mixture wherein the agent is dispersed in a matrix comprising the polymer and the starch; and compressing the mixture to form said tablet.




Fig. 1




Fig. 2




Fig. 3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/23403

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/4745 A61K9/20 A61K9/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 16442 A (JU TZU CHI ROBERT ;UPJOHN CO (US)) 8 April 1999 (1999-04-08) page 2, line 4 – line 13 page 2, line 32 – line 36 page 3, line 1 – line 11 page 3, line 20 – line 29 examples 9-11 ---	1-18
Y	WO 90 15058 A (UPJOHN CO) 13 December 1990 (1990-12-13) abstract; claims ---	1-18
Y	WO 02 36123 A (UPJOHN CO ;MCBRINN SYLVIA (US); ANDERSON RICHARD W (US)) 10 May 2002 (2002-05-10) cited in the application page 11, line 8 –page 12, line 27 claims ---	1-18
-/--		

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

21 November 2003

Date of mailing of the International search report

02/12/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Giménez Miralles, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/23403

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 59477 A (JANS EUGENE MARIE JOZEF ; JANSSEN PHARMACEUTICA NV (BE); VANDECROYNS) 12 October 2000 (2000-10-12) page 1, line 4 - line 12 page 8, line 9 page 10, line 26 -page 13, line 3 page 20, line 21 -page 24, line 19 examples ---	1-18
Y	WO 97 04752 A (DURAMED PHARMACEUTICALS INC) 13 February 1997 (1997-02-13) page 13, line 36 -page 14, line 8 page 15, line 1 -page 16, line 7 page 16, line 34 -page 17, line 29 page 19, line 1 - line 15 example 1 ---	1-18
Y	WO 99 09066 A (CARRIERE FRANCOIS ; DUMOULIN YVES (CA); ROUGIER INC (CA)) 25 February 1999 (1999-02-25) page 11, line 5 - line 18 page 13, line 26 - line 32 examples 2B,4B,6B,8B ---	1-18
Y	EP 0 933 079 A (CERESTAR HOLDING BV) 4 August 1999 (1999-08-04) cited in the application examples ---	1-18
A	WO 99 45924 A (ROUSSEAU LAURENCE ; SMITHKLINE BEECHAM PLC (GB); SMITHKLINE BEECHAM) 16 September 1999 (1999-09-16) examples 3-5 ---	1-18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/23403

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 14-17 because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: 1-18 partially because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 14-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 14-17

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 1-18 partially

Present independent claims 1, 14 and 18 relate to an extremely large number of possible pharmaceutical compositions containing as active agent a tricyclic amine defined in terms of a Markush formula embracing a vast number of possible chemical compounds. Support within the meaning of Article 6 PCT and/or sufficient disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compositions claimed, namely those wherein the active agent contains a pericondensed 5-membered imidazol ring ($D=N$; $n=0$), such as e.g. sumanirole, and closely related homologs. Other possible compounds, particularly those wherein D is not N , and $n=1$, are not sufficiently disclosed in the description and/or illustrated by means of examples, and are considered to represent merely a speculative generalisation of the actually disclosed subject-matter. It is considered that the scope of the claims is not commensurate with the extent of the disclosure.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been restricted to those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compositions wherein the active agent is one of those as claimed in claims 8-13 and the examples, and closely related homologs.

Moreover, present independent claims 1, 13 and 18 relate to compositions wherein one technical feature (starch) is defined/characterized by reference to an intrinsic property or characteristic thereof expressed in terms of a parameter, namely: "tensile strength of at least about 0.15 kN cm⁻² at a solid fraction of 0.8". The use of this parameter in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameter the applicant has chosen to employ with what is set out in the prior art,

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

i.a. because this parameter is not described/used in the relevant prior art, and because the values obtained for this parameter depend on the method/conditions of measurement of both tensile strength and solid fraction. The lack of clarity is such as to render a meaningful complete search impossible.

Consequently, the search has been carried out, ignoring said parametric definition, for sustained-release formulations comprising the technical feature "pregelatinized starch", as disclosed in the description in connection with the examples, and in claims 2 and 13.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/23403

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9916442	A 08-04-1999		AU 742941 B2 AU 9296498 A BR 9812687 A CA 2301869 A1 CN 1268890 T EP 1017391 A2 FI 20000720 A HU 0004586 A2 JP 2001517701 T NO 20001624 A PL 339946 A1 RU 2205007 C2 SK 3612000 A3 WO 9916442 A2 US 6197339 B1 US 2001053386 A1	17-01-2002 23-04-1999 22-08-2000 08-04-1999 04-10-2000 12-07-2000 29-03-2000 28-06-2001 09-10-2001 29-03-2000 15-01-2001 27-05-2003 12-09-2000 08-04-1999 06-03-2001 20-12-2001
WO 9015058	A 13-12-1990		AT 117688 T AU 626427 B2 AU 5743890 A CA 2051697 A1 DE 69016430 D1 DE 69016430 T2 DK 480939 T3 EP 0480939 A1 ES 2067744 T3 FI 96310 B FI 944704 A ,B, HK 65397 A HU 60269 A2 HU 9500660 A3 JP 2955358 B2 JP 4506071 T KR 167346 B1 NO 914827 A RU 2023712 C1 WO 9015058 A1 US 5436240 A US 5273975 A	15-02-1995 30-07-1992 07-01-1991 10-12-1990 09-03-1995 01-06-1995 10-07-1995 22-04-1992 01-04-1995 29-02-1996 07-10-1994 23-05-1997 28-08-1992 28-11-1995 04-10-1999 22-10-1992 15-01-1999 07-02-1992 30-11-1994 13-12-1990 25-07-1995 28-12-1993
WO 0236123	A 10-05-2002		AU 1122602 A BR 0115071 A CA 2421705 A1 EP 1330248 A2 NO 20031923 A WO 0236123 A2 US 2002107257 A1 US 2003212065 A1	15-05-2002 29-07-2003 10-05-2002 30-07-2003 27-06-2003 10-05-2002 08-08-2002 13-11-2003
WO 0059477	A 12-10-2000		AU 3963800 A BG 105857 A BR 0009437 A CA 2371940 A1 CN 1345233 T CZ 20013375 A3 EE 200100505 A WO 0059477 A1 EP 1169024 A1	23-10-2000 30-04-2002 15-01-2002 12-10-2000 17-04-2002 15-05-2002 16-12-2002 12-10-2000 09-01-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/23403

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0059477	A		HR 20010700 A1 HU 0200611 A2 JP 2002541090 T NO 20014724 A NZ 514890 A SK 13542001 A3	30-04-2003 29-07-2002 03-12-2002 28-09-2001 30-05-2003 06-08-2002
WO 9704752	A	13-02-1997	CA 2227887 A1 CN 1197387 A EP 0840599 A1 JP 2002504069 T WO 9704752 A1 WO 9704753 A1 US 5908638 A	13-02-1997 28-10-1998 13-05-1998 05-02-2002 13-02-1997 13-02-1997 01-06-1999
WO 9909066	A	25-02-1999	CA 2211778 A1 AU 8724198 A WO 9909066 A1	14-02-1999 08-03-1999 25-02-1999
EP 0933079	A	04-08-1999	EP 0933079 A1 JP 11269202 A US 6143324 A	04-08-1999 05-10-1999 07-11-2000
WO 9945924	A	16-09-1999	AU 748396 B2 AU 3033299 A CA 2323177 A1 CN 1292696 T WO 9945924 A1 EP 1061918 A1 HU 0101043 A2 JP 2002506031 T NO 20004491 A NZ 505807 A PL 342600 A1 TR 200002626 T2 US 6451343 B1 ZA 9901921 A BR 9908374 A	06-06-2002 27-09-1999 16-09-1999 25-04-2001 16-09-1999 27-12-2000 28-12-2001 26-02-2002 08-09-2000 31-01-2003 18-06-2001 21-03-2001 17-09-2002 11-09-2000 31-10-2000